1. Stimulus bill packs a windfall for FDA and COVID-19 drug developers — Roche nixes Tecentriq bladder cancer accelerated approval — AI uncovers Lilly's Olumiant as potential Alzheimer's treatment See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice

Nuvasive Stock

Discussion in 'NuVasive' started by Anonymous, Mar 5, 2013 at 11:46 AM.

  1. Anonymous

    Anonymous Guest

    At just under $20 a share this stock is extremely overpriced. It has been rallying since October when it it was around $12 per share.

    What is driving this increase?
  2. Anonymous

    Anonymous Guest

    Short term momentum due to the rising market. This stock will eventually head back down to the $11-12 and then maybe even lower.